Cartalax

CARTALAX 20MG provides Cartalax as lyophilized powder in a 3 mL vial. The specification table summarizes the named compound and catalog presentation.

Selected Nonclinical Research

Cartalax has been referenced in nonclinical literature, primarily in cell-culture models examining fibroblast proliferation markers and markers associated with cellular senescence. Published work from the Khavinson group has described effects of short bioregulatory peptides on expression of proliferation-associated and senescence-associated proteins in cell-culture systems.

Changes in aging-related markers in cartilage cells: In a chondrocyte study, AED was reported to normalize the aging-associated pattern of increased p16, p21, p53, TNF-α, and IL-1α and decreased Sirt1. This supports investigation of cellular senescence in cartilage cells, but does not demonstrate cartilage regeneration.

Increased collagen I and sirtuin expression in cultured fibroblasts: In human-derived skin fibroblasts undergoing replicative aging in laboratory culture, AED increased expression of collagen I, sirtuin-1, and sirtuin-6. These are markers relevant to extracellular matrix production and cellular aging; the experiment did not measure joint repair.

Reduced MMP-9 expression in aging fibroblast cultures: AED was among the peptides that reduced the age-associated increase in matrix metalloproteinase-9 (MMP-9), an enzyme involved in extracellular matrix remodeling. This finding concerns enzyme expression rather than demonstrated tissue restoration.

Reduced apoptosis-related activity in aging fibroblast cultures: In that same 2016 study, AED suppressed the age-associated increase in caspase-dependent apoptosis, assessed using caspase-3-related measurements. This supports further study of its effects on programmed cell death in cultured cells.